Cyclana Bio identifies novel therapeutic targets for endometriosis

Cyclana Bio has secured UK regulatory approval to launch PEMP, a 500-patient observational study investigating the biological mechanisms underlying endometriosis, a condition affecting 10% of women of reproductive age. The trial, led by investigators at Cambridge University Hospitals NHS Foundation Trust and North West Anglia NHS Foundation Trust, will collect biopsies and menstrual fluid to create three-dimensional in vitro models that replicate endometrial tissue physiology. Researchers expect the data on tissue-level dynamics comparing women with and without endometriosis will clarify the role of the extracellular matrix in disease manifestation and determine whether a single treatment or personalized medicine approach is required. Funded by a £5 million pre-seed round, the project has already begun recruitment across two UK hospitals and represents a methodological shift: moving from fragmented molecular studies to whole-tissue analysis that reveals causal patterns. For longevity-conscious readers, this signals the emergence of predictive biomarkers and preventive therapeutic strategies in one of the most prevalent chronic inflammatory conditions affecting women.